Chaqour, Brahim http://orcid.org/0000-0002-8516-4324
Duong, Thu T.
Yue, Jipeng
Liu, Tehui
Camacho, David
Dine, Kimberly E. http://orcid.org/0000-0001-5569-7261
Esteve-Rudd, Julian
Ellis, Scott
Bennett, Jean http://orcid.org/0000-0003-3378-8263
Shindler, Kenneth S. http://orcid.org/0000-0003-2417-258X
Ross, Ahmara G. http://orcid.org/0000-0002-7527-3121
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY019014, EY030163, EY030163)
U.S. Department of Health & Human Services | NIH | National Eye Institute
Robert Wood Johnson Foundation (Harold Amos Faculty Development Award, Harold Amos Faculty Development Award)
Research to Prevent Blindness
F. M. Kirby Foundation
Gyroscope Therapeutics Limited, a Novartis Company; Paul and Evanina Mackall Foundation Trust; Center for Advanced Retinal and Ocular Therapeutics
U.S. Department of Health & Human Services | NIH | National Eye Institute
Gyroscope Therapeutics Limited, a Novartis Company; Linda Pechenik Montague Investigator Award; Paul and Evanina Mackall Foundation Trust; Center for Advanced Retinal and Ocular Therapeutics
Article History
Received: 29 September 2023
Revised: 12 December 2023
Accepted: 19 December 2023
First Online: 10 January 2024
Competing interests
: AGR and KSS hold intellectual property relevant to this study and received research funding from Gyroscope Therapeutics Limited, a Novartis Company. JE-R and SE are full time employees of Gyroscope. Other authors declare no conflict of interests.
: All experiments were performed in accordance with relevant guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, as well as with institutional and federal regulations.